Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243419 | 0.87 | CA2 (0.40) | KMT2AL3MBTL1FAAHPRSS1PRSS2 | |
| SCHEMBL6964204 | 0.81 | FAAH (0.38) | KMT2AL3MBTL1FAAHPRSS1PRSS2 | |
| SCHEMBL422010 | 0.80 | USP2 (0.51) | KMT2AIDO1LOXL2TAAR1L3MBTL1 | |
| SCHEMBL925715 | 0.78 | KMT2A (0.50) | KMT2AIDO1TAAR1L3MBTL1EGFR | |
| SCHEMBL9421733 | 0.78 | FAAH (0.62) | KMT2AIDO1LOXL2TAAR1L3MBTL1 | |
| SCHEMBL29221410 | 0.78 | CA2 (0.41) | KMT2AL3MBTL1FAAHPRSS1PRSS2 | |
| SCHEMBL66512 | 0.77 | APLNR (0.50) | IDO1TAAR1CA1CA2CA12 | |
| SCHEMBL777188 | 0.76 | KMT2A (0.44) | KMT2AIDO1LOXL2TAAR1L3MBTL1 | |
| SCHEMBL14536592 | 0.76 | ESR1 (0.46) | IDO1TAAR1L3MBTL1LMNACA1 | |
| SCHEMBL1149296 | 0.76 | KMT2A (0.48) | KMT2AIDO1TAAR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105255-B | Mild synthesis method of diaryl thioether | 江西理工大学 | 2020-11-03 | — | — | CN | claimed |
| CN-110452146-A | Trifluoromethyl seleno-amino acids derivative and preparation method thereof | UNIV WUHAN TECH | 2019-11-15 | — | — | CN | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| CN-119730854-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| CN-119264303-A | Pendant group functionalized fluorine-containing polymer, preparation method of fluorine-containing polymer, ion exchange membrane and application | 佛山绿动氢能科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-1995009158-A1 | TRICYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| EP-0627443-A1 | 3,4'-DIDEOXYMYCAMINOSYLTYLONOLIDE DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| EP-0169512-B1 | NOVEL TYLOSIN DERIVATIVES | Sanraku Incorporated (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0169512-A1 | Novel tylosin derivatives | Sanraku Incorporated (JP) | 1986-01-29 | — | — | EP | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | KMT2A 2755/4885IDO1 1078/4885LOXL2 801/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | KMT2A 3281/4885IDO1 687/4885LOXL2 739/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | KMT2A 3331/4885IDO1 124/4885LOXL2 91/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | KMT2A 3462/4885IDO1 3249/4885LOXL2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.